EP0167567A1 - Traitement de metastases - Google Patents
Traitement de metastasesInfo
- Publication number
- EP0167567A1 EP0167567A1 EP19850900412 EP85900412A EP0167567A1 EP 0167567 A1 EP0167567 A1 EP 0167567A1 EP 19850900412 EP19850900412 EP 19850900412 EP 85900412 A EP85900412 A EP 85900412A EP 0167567 A1 EP0167567 A1 EP 0167567A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- forskolin
- analogs
- group
- hydroxy
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
Definitions
- This invention concerns methods and compositions for the treatment of tumor-induced metastasis, in particular, hematogeneous metastasis.
- the U. S. Government has rights in this invention pursuant to grants Nos. CA 13943 and CA 07340 provided by the U. S. Public Health Service.
- the hematogeneous metastatic process begins with the detachment of tumor cells from the primary tumor followed by intravasation with direct shedding of tumor cells into circulation. Although most tumor cells in circulation are quickly destroyed by various mechanisms, a few viable cells may be arrested in the microva ⁇ culature or otherwise may adher to endothelial surfaces.
- thrombotic material consisting of platelets, erythrocytes and fibrin. Thrombus formation appears to be a significant event in the establishment of tumor colonies in the capillary beds of various organs. Blood platelets also appear to play an important role in tumor metastasis; it has been demonstrated that many metastasizing tumor cell lines induce platelet aggregation both in vitro and in vivo. Furthermore, upon aggregation, platelets release a substance or substances which promote tumor growth.
- anticoagulants and anti-aggregating agents such as heparin, warfarin (Hagmar and Norrby, Vol. 5 Int. J. Cancer, pp. 72-84, [1970]; Lione and Bosmann, Vol. 2 Cell Biol. Int. Res., pp. 81-86 [1972]; Hoover and Ketcham, Vol. 35 Cancer, pp. 5-14 [1975]); aspirin (Gasic et al., Lancet II, pp. 932-933 [1972]; Wood and Hilgard, Lancet II, pp. 1416-1416 [1972]; Hilgard et al., Vol.
- PKI 2 prostacyclin 2
- PKI 2 a potent inhibitor of platelet aggregation
- Forskolin compounds are generally defined as labdane diterpenoids having the general formula:
- R 1 is hydrogen or a hydroxy or alkoxy, sulfonate or carbonate group
- R 2 is a hydroxy, carbonate, acetyl, or acetoxy or alkanoyl group
- R 3 is a hydroxy, carbonate, acetyl or acetoxy group
- R 4 is hydrogen or a hydroxy or alkoxy, sulfonate or carbonate group
- R 5 is either double-bonded oxygen or separately bound hydrogen and hydroxy groups
- R 6 is a lower alkene or oxygen.
- the forskolin blocks human platelet aggregation (induced by a wide variety of aggregation stimulators) by stimulating membrane adenylate cyclase thereby increasing several-fold the intracellular concentrations of cyclic AMP and inhibiting the tumor cell-platelet interactions which seem to play a role in tumor metastasis.
- Forskolin may be unique in its action and perhaps interacts directly with the catalytic subunit of adenylate cyclase.
- forskolin's high activity coupled with its low toxicity suggest that it can be a highly effective agent in reducing metastasis.
- forskolin analogs with similar properties include various modifications of the groups labeled R 1 to R 6 in formula I above.
- the 6-hydroxy group may be acetylated.
- the 7-acetyl group may be removed or replaced by r-alkaroyl or tosyl groups.
- the delta 14 15 bond may be substituted by oxygen.
- 6,7-dicarbonate may also be effective.
- the 6-acetyl-7-deacetyl derivative also appears to be active as do compounds where the chain length of the 6-alkanoyl group is increased or diethylarainocthyl groups are introduced at the 1 -position.
- 7-Deacetyl-11-deoxo-11 beta-hydroxyforskolin and 1-methyl-6 acetyl-7 deacetyl derivatives also appear to be pharmacologically active.
- the forskolin compounds described above may be administered alone or in conjunction with other agents.
- the forskolin compounds may be combined with nucleoside transport inhibitors which retard the uptake of adenosine by red blood cells and the like; such inhibitors include p-nitrobenzylthioinosine and dilazep.
- Our compounds may also be combined with agents that block the action of cAMP phosphodiesterase in converting cAMP to AMP, such as theophylline analogs, or compounds that both inhibit nucleoside transport and block cAMP conversion, such as dipyridamole and its analogs (i.e., RA-233), oxagrelate and papaverine.
- the forskolin compounds may be combined with other compounds that act upon adenylate cyclase in different fashions to create a synergistic effect; such compounds include adenosine analogs and prostacyclins.
- Fig. 1 is a graph plotting in vitro human platelet aggregation induced by the melanoma cells.
- A control
- B after treatment of platelet-rich plasma with forskolin.
- Figs. 2a-2d are photographs comparing representative lung specimens from forskolin-treated and untreated mice.
- Example I A mouse melanoma subline, B16-F10, (highly metastatic to the lungs) was obtained from EG & G Mason Research Institute, Worcester, MA, and adapted to growth in cell culture. The cultured cells were harvested by 1 min of trypsinization (0.25% trypsin-0.1% EDTA) or with the use of a rubber policeman, washed gently three times with Hank's balanced salts solution (HBBS, free of Ca and Mg ++ ). The cell viability determined by Trypan Blue exclusion ranged from 70-95% in the separate experiments. Freshly drawn whole blood from healthy adult human donors was anticoagulated with heparin (5 units/ml). The donors had not ingested antiplatelet drugs for at least 10 days.
- Platelet-rich plasma was separated by centrifugation of the whole blood and platelet aggregation was measured in PRP by recording the increase in light transmission after the addition of the tumor cells.
- Washed B16-F10 cell suspensions (2 x 10 7 /ml) were treated with potato apyrase (1 unit/ml) for about 5 min to degrade exogenous adenine nucleotides. Fifty microliters of the cell suspension was then added to the platelet-rich plasma after an incubation of 5 min with (A) 5 microliters DMSO (10% in saline) (Control) or (B) 5 microliters forskolin (200 micro Molars in DMSO 10% in saline).
- Fig. 1 shows that B16-F10 cells (2 x 10 6 /ml) induced human blood platelet aggregation after a lag of about 1 min. However, if the PRP was preincubated (5 min) with the low concentration of forskolin (2 micromolars), the tumor cell-induced platelet aggregation was strongly blocked.
- Example II Intravenous tail vein injections of B16-F10 cells (2 or 3 x 10 5 cell/mouse) to C57BL/6 mice (5-8 weekB old, 6-9 mice/group), produced a large number of pulmonary tumor foci after 9 or 14 days. However, if the mice were treated with a single intraperitoneally dose of forskolin (82 micrograms/mouse, i.e. 4-5 mg/kg) given 30 or 60 min before the tumor cell injections, reductions in tumor colonization of greater than 70 percent were observed. Similar results were seen in three separate experiments. Washed B16-F10 tumor cells (2 or 3 x 10 5 ) in 100 microliters Hanks balanced salts solution were injected from the tail vein 60 min (Exp. 1) or 30 min (Exp.
- Fig. 2 presents typical specimens of lungs from untreated and forskolin-treated mice of experiments 2 and 3. Examination under a dissecting microscope revealed that the tumor foci in the forskolin-treated mice were smaller and more superficial than in the untreated mice, which were larger and more deeply embedded. A summary of these experiments is provided in Table 1 below.
- EXAMPLE IV The in vivo experimental procedure of Example II above was also repeated using a combination of forskolin and oxagrelate. Intraperitoneal injections of the combination (oxagrelate: 40-45 mb/kg and forskolin: 1-1.5 mg/kg) 30 minutes before tail vein injections of the B16-F10 tumor cells reduced tumor colonization in the lungs of the mice 40 to 70 percent.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un procédé de réduction de l'incidence de métastases chez des patients victimes de tumeurs consiste à administrer de la forskoline ou ses analogues, puissants inhibiteurs de l'agglutination de thrombocytes. Les composés de forskoline sont définis généralement comme diterpénoïdes de labdane et présentent la formule générale (I). Ces composés peuvent être administrés seuls ou en combinaison avec d'autres inhibiteurs de l'agglutination de thrombocytes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56118283A | 1983-12-14 | 1983-12-14 | |
US561182 | 1983-12-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0167567A1 true EP0167567A1 (fr) | 1986-01-15 |
Family
ID=24240966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19850900412 Withdrawn EP0167567A1 (fr) | 1983-12-14 | 1984-12-13 | Traitement de metastases |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP0167567A1 (fr) |
WO (1) | WO1985002616A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3502686A1 (de) * | 1985-01-26 | 1986-08-14 | Hoechst Ag, 6230 Frankfurt | Verfahren zur herstellung von labdan-derivaten und ihre verwendung als arzneimittel |
DE3502685A1 (de) * | 1985-01-26 | 1986-09-04 | Hoechst Ag, 6230 Frankfurt | Forskolin, seine analoge und derivate, verfahren zu deren herstellung mittels mikrobieller umwandlungen und die anwendung dieser verbindungen als arzneimittel |
FR2613935B1 (fr) * | 1987-04-15 | 1989-12-01 | Roussel Uclaf | Association renfermant a titre de principes actifs, un analgesique central et la forskoline |
IN166900B (fr) * | 1987-06-03 | 1990-08-04 | Hoechst India |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4517200A (en) * | 1982-12-27 | 1985-05-14 | Schering-Plough Corporation | Method for treating allergic reactions with forskolin |
US4476140A (en) * | 1983-05-16 | 1984-10-09 | Yale University | Composition and method for treatment of glaucoma |
-
1984
- 1984-12-13 WO PCT/US1984/002038 patent/WO1985002616A1/fr not_active Application Discontinuation
- 1984-12-13 EP EP19850900412 patent/EP0167567A1/fr not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO8502616A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1985002616A1 (fr) | 1985-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4751224A (en) | Treatment of metastasis | |
Agarwal et al. | Forskolin: a potential antimetastatic agent | |
Harrison et al. | Alterations of vascular reactivity in atherosclerosis | |
Ferrero et al. | Activity in vitro of resveratrol on granulocyte and monocyte adhesion to endothelium | |
Casals-Stenzel | Protective effect of WEB 2086, a novel antagonist of platelet activating factor, in endotoxin shock | |
CA2564637C (fr) | Extraits bruts d'andrographis paniculata | |
Beasley et al. | Endotoxin inhibits contraction of vascular smooth muscle in vitro | |
JP6669762B2 (ja) | 移植後の造血幹細胞の生着効率の増進に使用するための組成物 | |
KR20010015807A (ko) | 9-데옥시-2',9-알파-메타노-3-옥사-4,5,6-트리노르-3,7-(1',3'-인터페닐렌)-13,14-디하이드로-프로스타글란딘에프1을 이용한 말초 혈관 질환의 치료 | |
JP2004505047A (ja) | 複合治療による癌治療 | |
JP2008291040A (ja) | 幹細胞と前駆細胞のリクルートメントにおけるニコチン受容体アゴニスト | |
KR20010072957A (ko) | H2 수용체 작용제 및 기타 t-세포 활성화제를 사용한t-세포(cd4+ 및 cd8+) 활성화 및 보호 방법 | |
BR112013017878B1 (pt) | Método para melhorar o enxerto de células-tronco hematopoéticas e composições derivadas | |
CA1220139A (fr) | Composes et methode de traitement pour ameliorer la circulation | |
EP0167567A1 (fr) | Traitement de metastases | |
Benzi et al. | Effect of lysergide and nimergoline on glucose metabolism investigated on the dog brain isolated in situ | |
JPH09507490A (ja) | 増殖性障害、転移および薬物耐性腫瘍の治療用バナジン酸塩化合物 | |
IL237119A (en) | Heterocyclic carboxamides for the treatment of viral diseases | |
Schirner et al. | The prostacyclin analogue cicaprost inhibits metastasis of tumours of R 3327 MAT Lu prostate carcinoma and SMT 2A mammary carcinoma | |
Richel et al. | Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia | |
DRAGO et al. | Control of metastases in the Nb rat prostatic adenocarcinoma model | |
Hatori et al. | Differences in infarct size with lidocaine as compared with bretylium tosylate in acute myocardial ischemia and reperfusion in pigs | |
Wang | Activated macrophage-mediated endogenous prostaglandin and nitric oxide-dependent relaxation of lymphatic smooth muscles | |
JPS62265223A (ja) | 成長促進剤としてのアベルメクチン | |
Darius et al. | Inhibition of the platelet activating factor mediated component of guinea pig anaphylaxis by receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB LI LU NL SE |
|
17P | Request for examination filed |
Effective date: 19851202 |
|
17Q | First examination report despatched |
Effective date: 19870820 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19871231 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: PARKS, ROBERT, E., JR. Inventor name: AGARWAL, KAILASH, C. |